Previously, dual p110δ/γ inhibition with the pharmaceutical IPI-145 has been shown to be ineffective in combination with anti-PD-L1 therapy in murine MOC2 HNSCC [26]. This evidence concerns the gene PIK3CD and head and neck squamous cell carcinoma.